AU2017336889B2 - Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof - Google Patents

Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof Download PDF

Info

Publication number
AU2017336889B2
AU2017336889B2 AU2017336889A AU2017336889A AU2017336889B2 AU 2017336889 B2 AU2017336889 B2 AU 2017336889B2 AU 2017336889 A AU2017336889 A AU 2017336889A AU 2017336889 A AU2017336889 A AU 2017336889A AU 2017336889 B2 AU2017336889 B2 AU 2017336889B2
Authority
AU
Australia
Prior art keywords
crystalline form
preparation
compound
formula
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017336889A
Other languages
English (en)
Other versions
AU2017336889A1 (en
Inventor
Congxin Liang
Lihua Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Equinox Sciences LLC
Original Assignee
Equinox Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equinox Sciences LLC filed Critical Equinox Sciences LLC
Publication of AU2017336889A1 publication Critical patent/AU2017336889A1/en
Application granted granted Critical
Publication of AU2017336889B2 publication Critical patent/AU2017336889B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017336889A 2016-09-29 2017-09-29 Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof Active AU2017336889B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610866253 2016-09-29
CN201610866253.6 2016-09-29
PCT/CN2017/104506 WO2018059556A1 (zh) 2016-09-29 2017-09-29 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
AU2017336889A1 AU2017336889A1 (en) 2019-04-11
AU2017336889B2 true AU2017336889B2 (en) 2021-11-25

Family

ID=61763329

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017336889A Active AU2017336889B2 (en) 2016-09-29 2017-09-29 Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof

Country Status (17)

Country Link
US (3) US11053224B2 (OSRAM)
EP (1) EP3502105B8 (OSRAM)
JP (2) JP7253491B2 (OSRAM)
KR (1) KR102289684B1 (OSRAM)
CN (1) CN108884080B (OSRAM)
AU (1) AU2017336889B2 (OSRAM)
CA (2) CA3035124C (OSRAM)
EA (1) EA201990688A1 (OSRAM)
ES (1) ES2914294T3 (OSRAM)
IL (2) IL265266B2 (OSRAM)
MY (1) MY194364A (OSRAM)
PH (1) PH12019500681A1 (OSRAM)
PL (1) PL3502105T3 (OSRAM)
SG (1) SG11201901962QA (OSRAM)
TW (1) TWI647224B (OSRAM)
WO (1) WO2018059556A1 (OSRAM)
ZA (1) ZA201901717B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018059556A1 (zh) * 2016-09-29 2018-04-05 贝达药业股份有限公司 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
CN115531352B (zh) 2020-09-14 2025-04-25 视点制药公司 可生物蚀解的眼部药物递送插入剂及治疗方法
BR112023018649A2 (pt) * 2021-03-16 2023-10-10 Hk Inno N Corp Forma cristalina e método para preparar uma forma cristalina
JP7138982B1 (ja) 2021-09-24 2022-09-20 東海物産株式会社 アンセリンの結晶及びその製造方法
CA3245205A1 (en) 2022-03-11 2023-09-14 EyePoint Pharmaceuticals, Inc. METHOD FOR PREVENTING AGE-RELATED MACULAR DEGENERATION BY ADMINISTRATION OF A DRUG-DELIVERING OPHTHALMIC INSERT
TW202345804A (zh) 2022-03-11 2023-12-01 美商視點製藥有限公司 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法
TW202400143A (zh) 2022-03-11 2024-01-01 美商視點製藥有限公司 用於治療眼睛病況之持續給藥方案
TW202448436A (zh) 2023-04-11 2024-12-16 美商視爾普斯眼科公司 含有酪胺酸激酶抑制劑之眼部植入物
CN117143083A (zh) * 2023-08-30 2023-12-01 沈阳药科大学 VEGFR抑制剂Vorolanib的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033562A2 (en) * 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213185A (pt) 2001-10-10 2004-09-14 Sugen Inc Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
EP2145505A1 (de) * 2007-05-07 2010-01-20 Baumer Electric AG Akustischer wandler
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2720943A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
RU2468022C2 (ru) 2008-05-23 2012-11-27 Шанхай Инститьют Оф Фармасьютикал Индастри Производные дигидроиндолона
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2264027A1 (en) 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CN106928114B (zh) * 2015-12-31 2020-07-28 韶远科技（上海)有限公司 含有脲基的环状手性氨基类化合物及其可放大工艺和用途
WO2018059556A1 (zh) 2016-09-29 2018-04-05 贝达药业股份有限公司 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033562A2 (en) * 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds

Also Published As

Publication number Publication date
ES2914294T3 (es) 2022-06-08
MY194364A (en) 2022-11-29
CA3253105A1 (en) 2025-07-08
KR102289684B1 (ko) 2021-08-12
CA3035124C (en) 2025-11-18
TW201815785A (zh) 2018-05-01
CN108884080B (zh) 2020-10-27
NZ751911A (en) 2024-07-26
US11053224B2 (en) 2021-07-06
JP2019529568A (ja) 2019-10-17
CN108884080A (zh) 2018-11-23
JP2023082086A (ja) 2023-06-13
BR112019006023A2 (pt) 2019-06-18
CA3035124A1 (en) 2018-04-05
JP7763203B2 (ja) 2025-10-31
TWI647224B (zh) 2019-01-11
HK1257194A1 (zh) 2019-10-18
EP3502105A1 (en) 2019-06-26
US20190233403A1 (en) 2019-08-01
IL311631A (en) 2024-05-01
WO2018059556A1 (zh) 2018-04-05
SG11201901962QA (en) 2019-04-29
IL265266B2 (en) 2024-08-01
EA201990688A1 (ru) 2019-08-30
EP3502105B8 (en) 2022-06-01
EP3502105A4 (en) 2020-04-15
PH12019500681A1 (en) 2019-11-25
ZA201901717B (en) 2019-11-27
EP3502105B1 (en) 2022-03-30
US12209080B2 (en) 2025-01-28
US20250188063A1 (en) 2025-06-12
PL3502105T3 (pl) 2022-07-11
US20220356173A1 (en) 2022-11-10
KR20190039823A (ko) 2019-04-15
AU2017336889A1 (en) 2019-04-11
IL265266A (en) 2019-05-30
JP7253491B2 (ja) 2023-04-06
IL265266B1 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
US20250188063A1 (en) Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof
JP7086118B2 (ja) Ｌ－オルニチンフェニルアセテートおよびその製造方法
CA2874815C (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof.
AU2015221466B2 (en) L-ornithine phenyl acetate and methods of making thereof
CN112770756A (zh) 一种Upadacitinib的晶型及其制备方法和用途
HK1257194B (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
BR112019006023B1 (pt) Forma cristalina, método de preparação da forma cristalina, e, composição farmacêutica
CN114601831A (zh) 乐伐替尼分子复合物及其制备方法
AU2021231396A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)